Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:ATCCode |
N05AX16
|
| gptkbp:brand |
gptkb:Rexulti
|
| gptkbp:CASNumber |
913611-97-9
|
| gptkbp:chemicalFormula |
C25H27N3O2S
|
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:eliminationHalfLife |
91 hours
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:brexpiprazole
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rexulti
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck |
| gptkbp:mechanismOfAction |
antagonist at serotonin 5-HT2A receptors
partial agonist at dopamine D2 receptors partial agonist at serotonin 5-HT1A receptors |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
anxiety
headache weight gain insomnia akathisia |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
schizophrenia |
| gptkbp:bfsParent |
gptkb:Otsuka_Holdings
|
| gptkbp:bfsLayer |
6
|